Gain exclusive insights on the perceived value and benefits of personalised medicine and on the key challenges and opportunities in relation to implementation from treating oncologists.
Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (US) is based on survey results from 50 US oncologists (33 medical oncologists and 17 haematologist-oncologists) and offers insights on what oncologists believe are the critical issues, challenges and opportunities within the personalised medicines space, and how oncologists intend to adopt personalised medicine in the future.
Quantitative Analysis | EU5 Report |
A great deal of anticipation and expectation surrounds personalised medicine. While there have been some notable successes, the promise of personalised medicine – right medicine, right patient, right time – has failed to materialise in many disease areas where a personalised approach could drive better patient outcomes. Concerns amongst key stakeholder groups remain, particularly in relation to development, access and implementation of personalised healthcare strategies. This survey provides US physician insights into personalised medicine within the oncology setting. By understanding what oncologists in the US think about the key challenges, opportunities and concerns, companies operating in the oncology market and seeking to leverage personalised medicine for their products can gain a deep understanding of what’s needed to drive long-term commercial success. | Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5) Based on survey results from 150 oncologists (104 medical oncologists and 46 haematologist-oncologists), the EU5 report offers insights on what oncologists in France, Germany, Spain, Italy and the UK believe are the critical issues, challenges and opportunities within the personalised medicines space, and how oncologists intend to adopt personalised medicine in the future. When you purchase both the US and EU5 reports, you will receive the US vs. EU5 Comparison Report. Contact FirstWord. |
Report Features | About the Survey |
Filled with charts and up-to-the-minute survey analysis, this report offers:
|
|
FirstView reports deliver unique insight into current and future pharma market dynamics through quantitative surveys with physicians. With the ability to query a 1-million strong online physician community worldwide, FirstView provides essential data to support effective decision making in major disease areas and on key industry issues.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
Learn more at www.firstwordgroup.com.
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved